Funding for this research was provided by:
H2020 European Institute of Innovation and Technology (17051)
Received: 25 June 2018
Accepted: 30 April 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: Ethical approval for the study was given by the Ethics Committee of the Medical Faculty of the Technical University of Munich (reference number 175/17 S). All participants gave written informed consent.
: Not applicable.
: The authors declare that they have no competing interests with regards to the submitted work. Outside the submitted work TG reported having received consulting fees from Actelion, Eli Lilly, Iqvia, Quintiles, MSC, Novartis, Roche Pharma, lecture fees from Biogen, Lilly, Parexel, Roche Pharma, and grants to his institution from Actelion and PreDemTech.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.